KR20220010552A - 항-abeta 백신 요법 - Google Patents
항-abeta 백신 요법 Download PDFInfo
- Publication number
- KR20220010552A KR20220010552A KR1020217041697A KR20217041697A KR20220010552A KR 20220010552 A KR20220010552 A KR 20220010552A KR 1020217041697 A KR1020217041697 A KR 1020217041697A KR 20217041697 A KR20217041697 A KR 20217041697A KR 20220010552 A KR20220010552 A KR 20220010552A
- Authority
- KR
- South Korea
- Prior art keywords
- vaccine composition
- liposomal vaccine
- disease
- administered
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810.1 | 2019-05-21 | ||
| EP19175810 | 2019-05-21 | ||
| EP19185593.1 | 2019-07-10 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20171549.7 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| EP20172205.5 | 2020-04-29 | ||
| PCT/EP2020/064172 WO2020234405A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220010552A true KR20220010552A (ko) | 2022-01-25 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217041697A Pending KR20220010552A (ko) | 2019-05-21 | 2020-05-20 | 항-abeta 백신 요법 |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI916375B (zh) * | 2020-06-25 | 2026-03-01 | 英商梅迪繆思有限公司 | 軸突損傷之預防 |
| WO2024156912A1 (en) * | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Anti-abeta vaccine therapy |
| WO2025109524A1 (en) * | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| CA2633399C (en) * | 2005-12-12 | 2016-01-26 | Ac Immune S.A. | Therapeutic vaccine |
| MX2011009654A (es) * | 2009-03-18 | 2011-10-12 | Ac Immune Sa | Metodo para uso terapeutico. |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| EP2632434B1 (en) | 2010-10-26 | 2025-08-20 | AC Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| MA52180A (fr) * | 2018-04-10 | 2021-02-17 | Ac Immune Sa | Vaccins thérapeutiques anti-abêta |
-
2020
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en not_active Ceased
- 2020-05-20 MY MYPI2021006840A patent/MY210394A/en unknown
- 2020-05-20 JP JP2021569155A patent/JP7701734B2/ja active Active
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 IL IL288252A patent/IL288252B1/en unknown
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko active Pending
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL288252A (en) | 2022-01-01 |
| JP2022533422A (ja) | 2022-07-22 |
| MY210394A (en) | 2025-09-18 |
| CN113853214A (zh) | 2021-12-28 |
| CA3138145A1 (en) | 2020-11-26 |
| SG11202112329RA (en) | 2021-12-30 |
| JP7701734B2 (ja) | 2025-07-02 |
| IL288252B1 (en) | 2026-06-01 |
| TW202110425A (zh) | 2021-03-16 |
| US20220226447A1 (en) | 2022-07-21 |
| WO2020234405A1 (en) | 2020-11-26 |
| BR112021023209A2 (pt) | 2022-01-18 |
| MX2021014102A (es) | 2022-02-11 |
| EP3972633A1 (en) | 2022-03-30 |
| CL2021003051A1 (es) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100996936B1 (ko) | 베타 아밀로이드 펩티드를 인식하는 인간화된 항체 | |
| TWI508975B (zh) | 單株抗體 | |
| US12324855B2 (en) | Method of safe administration of phosphorylated Tau peptide vaccine | |
| KR101236611B1 (ko) | 치료 백신 | |
| JP7701734B2 (ja) | 抗aベータワクチン療法 | |
| US20050123553A1 (en) | Amyloid beta-peptide and methods of use | |
| WO2015165980A2 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| JP3905126B2 (ja) | T細胞媒介疾患の治療の効力を検出又は監視する方法 | |
| EA049756B1 (ru) | Терапия с помощью вакцины против бета-амилоида | |
| HK40058406A (en) | Anti-abeta vaccine therapy | |
| JP2026503655A (ja) | 抗Aβワクチン療法 | |
| US20250049900A1 (en) | Method of safe administration of tau phosphopeptide conjugate | |
| HK40061379A (en) | Method of safe administration of phosphorylated tau peptide vaccine | |
| EA050855B1 (ru) | ЛИПОСОМА ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ИНДУКЦИИ АНТИТЕЛ К ФОСФОРИЛИРОВАННОМУ ПЕПТИДУ Tau |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |